Paul E Freiman is President and Chief Executive Officer of Neurobiological Technologies, Inc. (NTI). He is the former Chairman and Chief Executive Officer of Syntex Corporation where he had a long and successful career and was instrumental in the sale of Syntex to Roche Holdings for US$5.3 billion. Mr Freiman currently serves as Chairman of the board of Digital Gene Technologies and as a director of Burrill & Company, Penwest Pharmaceutical Co., Calypte Biomedical Corporation, Omware, Inc., PHYTOS Inc. and Otsuka America Pharmaceuticals, Inc. He has served as Chairman of the Pharmaceutical Manufacturers Association of America.